Similarly, pyoluteorin-derived analogs such as KS18 have shown remarkable efficacy in xenograft models of drug-resistant multiple myeloma, reinforcing the therapeutic relevance of Mcl-1 inhibition in resistant cancers. This evidence concerns the gene MCL1 and cancer.